'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

NCT04019873 · clinicaltrials.gov ↗

COMPLETED

Status

774

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Dolutegravir (DTG)
DRUG: Lamivudine (3TC)
DRUG: Rilpivirine (RPV)

Sponsor

ViiV Healthcare